pembrolizumab/KEYTRUDA®

DRUG2 trials

Sponsors

Antengene Biologics Limited, Biocity Biopharmaceutics Co., Ltd.

Conditions

Locally Advanced or Metastatic Solid TumorsUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Phase 1

A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

RecruitingNCT07327229

Antengene Biologics LimitedUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Start: 2026-02-27End: 2029-04-30Target: 132Updated: 2026-07-29

BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

RecruitingNCT07469774

Biocity Biopharmaceutics Co., Ltd.Locally Advanced or Metastatic Solid Tumors

Start: 2026-03-31End: 2028-12-31Target: 111Updated: 2026-05-28